Oragenics,
Inc. (OTCQB: OGEN)(OTCBB: OGEN) today announced it has received its
first patent approval in Europe for its ProBiora3®
products. The approval provides additional protection for ProBiora3’s
proprietary blend of three probiotic bacteria, specifically designed to
enhance oral health, whiten teeth and freshen breath. ProBiora3 is
currently being sold under the brand name Evora in the U.S. and in over
13 countries around the world.
European Patent No. 1659885, entitled “Compositions and Methods for the
Maintenance of Oral Health,” affords protection for ProBiora3 for use in
a broad spectrum of applications, including the prevention of tooth
decay and periodontal diseases, halitosis, and other therapeutic and
cosmetic applications. The claims further protect ProBiora3® in several
delivery forms, such as food supplements, tablets, and mouth rinses.
“This approval protects our oral probiotic franchise and adds value to
the product. We are the only comprehensive oral probiotics patented for
tooth and gingival health,” stated Dr. John N. Bonfiglio, President and
CEO, Oragenics, Inc. “We are committed to growing this product
throughout the European Union especially given how well-received
probiotics are by European consumers.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics has established an exclusive worldwide
channel collaboration for lantibiotics, a novel class of broad spectrum
antibiotics, with Intrexon Corporation Inc., a synthetic biology
company. The collaboration will allow Oragenics access to Intrexon's
proprietary technologies with the idea of accelerating the development
of much needed new antibiotics that will work against resistant strains
of bacteria. Oragenics also develops, markets and sells proprietary
probiotics specifically designed to enhance oral health for humans and
pets, under the brand names Evora
and ProBiora
in over 13 countries worldwide.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect the Company’s current views with respect to
future events and financial performance. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar expressions
that do not relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to our ability to
raise additional capital to sustain our operations beyond June 30, 2012
and those set forth in our most recently filed annual report on Form
10-K and quarterly report on Form 10-Q, and other factors detailed from
time to time in filings with the U.S. Securities and Exchange
Commission. We expressly disclaim any responsibility to update
forward-looking statements.
